MDGL FY 2012 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$738,000

Operating Income

-$61M

Net Income

-$63M

EPS (Diluted)

$-36.99

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$103M

Total Liabilities

$28M

Stockholders' Equity

$75M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$8M	-100.0%
Gross Profit	-$738,000	$6M	-112.1%
Operating Income	-$61M	-$45M	-34.5%
Net Income	-$63M	-$47M	-32.5%